J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft
Michael R. Bishop,James R. Anderson,John D. Jackson,Philip J. Bierman,Elizabeth C. Reed,Julie M. Vose,James O. Armitage,Phyllis I. Warkentin,Anne Kessinger +8 more
TL;DR: Mobilization of PBC with rHuGM-CSF alone is an effective method for patients who have received prior chemotherapy and have bone marrow abnormalities, that provided rapid and sustained restoration of hematopoietic function following high-dose chemotherapy.
Journal ArticleDOI
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Andrew D. Zelenetz,Leo I. Gordon,Jeremy S. Abramson,Ranjana H. Advani,Nancy L. Bartlett,Paolo Caimi,Julie E. Chang,Julio C. Chavez,Beth Christian,Luis Fayad,Martha Glenn,Thomas M. Habermann,Nancy L. Harris,Francisco J. Hernandez-Ilizaliturri,Mark S. Kaminski,Chris R. Kelsey,Nadia Khan,Susan Krivacic,Ann S. LaCasce,Amitkumar Mehta,Auayporn Nademanee,Rachel Rabinovitch,Nishitha Reddy,Erin Reid,Kenneth B. Roberts,Stephen D. Smith,Erin D Snyder,Lode J. Swinnen,Julie M. Vose,Mary A. Dwyer,Hema Sundar +30 more
TL;DR: The NCCN Guidelines Insights as mentioned in this paper highlight important updates for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.
Journal ArticleDOI
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry
Cesar O. Freytes,Fausto R. Loberiza,J. Douglas Rizzo,Asad Bashey,Christopher Bredeson,Mitchell S. Cairo,Robert Peter Gale,Mary M. Horowitz,Thomas R. Klumpp,Rodrigo Martino,Philip L. McCarthy,Arturo Molina,Santiago Pavlovsky,Andrew L. Pecora,Derek S. Serna,Tsuong Tsai,Mei-Jie Zhang,Julie M. Vose,Hillard M. Lazarus,Koen van Besien +19 more
TL;DR: Allo-HSCT is feasible for patients with lymphoma who have relapses after autologous hematopoietic stem cell transplantation and can result in prolonged survival for some, but it is usually not curative.
Journal ArticleDOI
Primary Mediastinal Large B-Cell Lymphoma: A Clinicopathologic Study of 43 Patients From the Nebraska Lymphoma Study Group
Ashraf A. Abou-Elella,Dennis D. Weisenburger,Julie M. Vose,Jeffrey P. Kollath,James C. Lynch,Martin Bast,Philip J. Bierman,Timothy C. Greiner,Wing C. Chan,James O. Armitage +9 more
TL;DR: The clinical features of PMLBL do not appear to be significantly different from those of nonmediastinal DLBL, and although the younger age of onset, slight female predominance, mediastinal location, and size of the mass may justify the recognition ofPMLBL as a clinical syndrome, additional evidence is needed.
Journal ArticleDOI
Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.
James O. Armitage,Julie M. Vose,James Linder,James Linder,Dennis D. Weisenburger,Douglas S. Harrington,John Casey,P. J. Bierman,S Sorensen,M Hutchins,D F Moravec +10 more
TL;DR: Patients with aggressive non-Hodgkin's lymphoma treated by oncologists in the Nebraska Lymphoma Study Group were immunophenotyped from biopsies performed before therapy was administered, and identification of a subgroup of patients who had a very poor prognosis with this treatment approach was identified.